» Articles » PMID: 34731619

MGlu Potentiation Enhances Prelimbic Somatostatin Interneuron Activity to Rescue Schizophrenia-like Physiological and Cognitive Deficits

Overview
Journal Cell Rep
Publisher Cell Press
Date 2021 Nov 3
PMID 34731619
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Evidence for prefrontal cortical (PFC) GABAergic dysfunction is one of the most consistent findings in schizophrenia and may contribute to cognitive deficits. Recent studies suggest that the mGlu subtype of metabotropic glutamate receptor regulates cortical inhibition; however, understanding the mechanisms through which mGlu positive allosteric modulators (PAMs) regulate PFC microcircuit function and cognition is essential for advancing these potential therapeutics toward the clinic. We report a series of electrophysiology, optogenetic, pharmacological magnetic resonance imaging, and animal behavior studies demonstrating that activation of mGlu receptors increases inhibitory transmission in the prelimbic PFC by selective excitation of somatostatin-expressing interneurons (SST-INs). An mGlu PAM reverses cortical hyperactivity and concomitant cognitive deficits induced by N-methyl-d-aspartate (NMDA) receptor antagonists. Using in vivo optogenetics, we show that prelimbic SST-INs are necessary for mGlu PAM efficacy. Collectively, these findings suggest that mGlu PAMs could reverse cortical GABAergic deficits and exhibit efficacy in treating cognitive dysfunction in schizophrenia.

Citing Articles

Further Optimization of the mGlu PAM VU6024578/BI02982816: Discovery and Characterization of VU6033685.

Reed C, Kalbfleisch J, Turkett J, Trombley T, Spearing P, Haymer D ACS Chem Neurosci. 2025; 16(4):745-752.

PMID: 39907715 PMC: 11843613. DOI: 10.1021/acschemneuro.5c00014.


Discovery of VU6024578/BI02982816: An mGlu Positive Allosteric Modulator with Efficacy in Preclinical Antipsychotic and Cognition Models.

Reed C, Kalbfleisch J, Turkett J, Trombley T, Nastase A, Spearing P J Med Chem. 2024; 67(24):22291-22312.

PMID: 39665415 PMC: 11684029. DOI: 10.1021/acs.jmedchem.4c02554.


Mu and Delta Opioid Receptors Modulate Inhibition within the Prefrontal Cortex Through Dissociable Cellular and Molecular Mechanisms.

Cole R, Joffe M bioRxiv. 2024; .

PMID: 39484533 PMC: 11526863. DOI: 10.1101/2024.10.17.618870.


GABAergic dysfunction in postmortem dorsolateral prefrontal cortex: implications for cognitive deficits in schizophrenia and affective disorders.

Hughes H, Brady L, Schoonover K Front Cell Neurosci. 2024; 18:1440834.

PMID: 39381500 PMC: 11458443. DOI: 10.3389/fncel.2024.1440834.


Evolutionary and functional analysis of metabotropic glutamate receptors in lampreys.

Zhuang R, Yan Z, Gao Y, Nurmamat A, Zhang S, Xiu M Fish Physiol Biochem. 2024; 50(4):1861-1877.

PMID: 38951427 DOI: 10.1007/s10695-024-01374-x.


References
1.
Manoach D, Press D, Thangaraj V, Searl M, Goff D, Halpern E . Schizophrenic subjects activate dorsolateral prefrontal cortex during a working memory task, as measured by fMRI. Biol Psychiatry. 1999; 45(9):1128-37. DOI: 10.1016/s0006-3223(98)00318-7. View

2.
Fung S, Webster M, Sivagnanasundaram S, Duncan C, Elashoff M, Weickert C . Expression of interneuron markers in the dorsolateral prefrontal cortex of the developing human and in schizophrenia. Am J Psychiatry. 2010; 167(12):1479-88. DOI: 10.1176/appi.ajp.2010.09060784. View

3.
Busche M, Konnerth A . Impairments of neural circuit function in Alzheimer's disease. Philos Trans R Soc Lond B Biol Sci. 2016; 371(1700). PMC: 4938029. DOI: 10.1098/rstb.2015.0429. View

4.
Lewis D, Cho R, Carter C, Eklund K, Forster S, Kelly M . Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am J Psychiatry. 2008; 165(12):1585-93. PMC: 2876339. DOI: 10.1176/appi.ajp.2008.08030395. View

5.
Wang H, Gao W . Cell type-specific development of NMDA receptors in the interneurons of rat prefrontal cortex. Neuropsychopharmacology. 2009; 34(8):2028-40. PMC: 2730038. DOI: 10.1038/npp.2009.20. View